Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read the full paper here.
Find similar posts on Hemostasis Today.
-
Sep 2, 2025, 13:59No Added Benefit of Surgery Within 72 Hours for Intracerebral Hemorrhage
-
Sep 2, 2025, 13:57DCB Technical Mastery Webinar by SCAI: European Best Practices for Complex Coronary Lesions
-
Sep 2, 2025, 13:51Zack Wheeler’s DVT Diagnosis Highlights Thoracic Outlet Syndrome Risks in Athletes: National Blood Clot Alliance
-
Sep 2, 2025, 13:39Heparins Outperform DOACs and FXII/FXI Inhibitors in Preventing Thrombin Generation: JTH Study
-
Sep 2, 2025, 08:51Perioperative Direct Oral Anticoagulant (DOAC) Dosing: Insights Dr. Sthanu Subramanian
-
Sep 3, 2025, 12:48Richa Sharma Shares ARCADIA Post-Hoc Findings: Apixaban Prevents Recurrent Stroke in ESUS Patients with LV Dysfunction
-
Sep 2, 2025, 13:55Nirav Dhanesha and LSU Health Shreveport Team Discover Neutrophil Integrin α9 as a Key Target in Subarachnoid Hemorrhage Recovery
-
Sep 2, 2025, 13:42Torsten Tonn Highlights Breakthrough in Blood Pharming: miRNA-30a-5p Knockout Restores Red Cell Differentiation
-
Sep 2, 2025, 13:05Ruah Alyamany: Evaluating Safety of TPO-RA Use in ITP After Splenectomy
-
Sep 2, 2025, 13:02Nicolas Hubacz: Visualizing Red Blood Cell Flow Through Zebrafish Capillaries
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 2, 2025, 14:02King Felipe VI Highlights Global Challenge of Cardiovascular Health at ESC Congress 2025
-
Sep 2, 2025, 14:00Jacek Lesinski: The Importance of Whole Blood and Plasma Donation
-
Sep 1, 2025, 08:09Wafik S. El-Deiry Opens Up on Recovery, Gratitude, and Book After Life-Changing Heart Surgery
-
Aug 31, 2025, 07:30Michael Albert: Being ‘Metabolically Healthy’ Doesn’t Eliminate Heart Disease Risk
-
Aug 31, 2025, 07:15Should 12-Month DAPT Be the Default After ACS? Mattia Galli Applauds Marco Valgimigli’s Talk